Cellular mechanisms of resistance in CML include point mutations in BCR-ABL gene (up to 40 identified), BCR-ABL amplification or activation of alternative survival signalling pathways (Sawyers et al, 2002; Weisberg and Griffin, 2003). The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.